PRELIMINARY STUDIES OF CARBOHYDRATE ANTIGEN 19-9 (CA19-9) ON HUMAN BREAST TUMORS

Abstract

A solid-phase immunoradiomertric assay sandwich technique (IRMA) was used for the determination of the carbohydrate antigen 19-9 (CA19-9) defined by a monoclonal antibody 125I-anti CA19-9 in sera of 10 premenopausal malignant breast tumors patients, 10 postmenopausal malignant breast tumors patients, and 10 benign breast tumors patients matched with one group of 10 healthy women as control. The data obtained demonstrated significant increase (P<0.05) in patients with benign and premenopausal malignant breast tumors, whereas highly significant increase (P<0.005) in patients with postmenopausal malignant breast tumors when matched with normal women. An Immunoradiometric Assay (IRMA) for the determination of cytosolic CA19-9 was developed, using 125I-anti CA19-9 antibody and found to be suitable for assessment of those antigens in benign and malignant breast tumors. The data revealed an increment of CA19-9 in the cytosolic fraction in comparison to the nuclear fraction.